Sartorius AG
General ticker "SUVPF" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $18.0B (TTM average)
Sartorius AG follows the US Stock Market performance with the rate: 26.5%.
Estimated limits based on current volatility of 0.3%: low 287.04$, high 288.70$
Factors to consider:
- Company pays dividends (annually): last record date 2026-03-30, amount 0.85$ (Y0.29%)
- Earnings for 15 months up through Q1 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [154.36$, 284.64$]
- 2025-12-31 to 2026-12-31 estimated range: [149.07$, 275.99$]
Financial Metrics affecting the SUVPF estimates:
- Negative: with PPE of 125.9 at the end of fiscal year the price was high
- Positive: 6.59 < Operating cash flow per share per price, % of 6.70
- Positive: 7.54 < Operating profit margin, % of 12.93
- Positive: -3.75 < Return on assets ratio (scaled to [-100,100]) of 0.82
- Positive: Inventory ratio change, % of -4.48 <= -0.75
- Positive: Interest expense per share per price, % of 1.46 <= 3.31
- Negative: Industry earnings per price (median), % of 0 <= 0
- Negative: Industry inventory ratio change (median), % of 1.17 > 0.28
- Positive: -0.03 < Industry operating cash flow per share per price (median), % of 0.74
Short-term SUVPF quotes
Long-term SUVPF plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | €3,395.70MM | €3,380.70MM | €3,536.77MM |
| Operating Expenses | €2,852.50MM | €2,943.50MM | €2,885.62MM |
| Operating Income | €543.20MM | €437.20MM | €651.16MM |
| Non-Operating Income | €-157.30MM | €-250.40MM | €-314.28MM |
| Interest Expense | €144.90MM | €212.63MM | €197.93MM |
| R&D Expense | €170.80MM | €196.80MM | €173.93MM |
| Income(Loss) | €385.90MM | €186.80MM | €336.87MM |
| Taxes | €95.90MM | €49.40MM | €106.56MM |
| Net Income(Loss)* | €205.20MM | €84.00MM | €154.84MM |
| Stockholders Equity | €2,067.30MM | €2,764.80MM | €2,705.79MM |
| Inventory | €1,036.70MM | €788.50MM | €791.90MM |
| Assets | €9,755.30MM | €10,103.00MM | €9,713.56MM |
| Operating Cash Flow | €853.60MM | €976.20MM | €655.75MM |
| Capital expenditure | €559.70MM | €409.90MM | €441.73MM |
| Investing Cash Flow | €-2,823.30MM | €-425.80MM | €-513.31MM |
| Financing Cash Flow | €2,165.70MM | €-128.30MM | €-410.45MM |
| Earnings Per Share** | €3.00 | €1.22 | €2.24 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.